Emerging therapeutic strategies for transplantation-induced acute kidney injury: protecting the organelles and the vascular bed.

Transplantation-induced acute kidney injury delayed graft function gene therapy ischemia reperfusion mineralocorticoid receptor mitochondrial energetic modulation stem cells unfolded protein response

Journal

Expert opinion on therapeutic targets
ISSN: 1744-7631
Titre abrégé: Expert Opin Ther Targets
Pays: England
ID NLM: 101127833

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 26 4 2019
medline: 11 3 2020
entrez: 26 4 2019
Statut: ppublish

Résumé

Renal ischemia-reperfusion injury (IRI) is a significant clinical challenge faced by clinicians in a broad variety of clinical settings such as perioperative and intensive care. Renal IRI induced acute kidney injury (AKI) is a global public health concern associated with high morbidity, mortality, and health-care costs. Areas covered: This paper focuses on the pathophysiology of transplantation-related AKI and recent findings on cellular stress responses at the intersection of 1. The Unfolded protein response; 2. Mitochondrial dysfunction; 3. The benefits of mineralocorticoid receptor antagonists. Lastly, perspectives are offered to the readers. Expert opinion: Renal IRI is caused by a sudden and temporary impairment of blood flow to the organ. Defining the underlying cellular cascades involved in IRI will assist us in the identification of novel interventional targets to attenuate IRI with the potential to improve transplantation outcomes. Targeting mitochondrial function and cellular bioenergetics upstream of cellular damage may offer several advantages compared to targeting downstream inflammatory and fibrosis processes. An improved understanding of the cellular pathophysiological mechanisms leading to kidney injury will hopefully offer improved targeted therapies to prevent and treat the injury in the future.

Identifiants

pubmed: 31022355
doi: 10.1080/14728222.2019.1609451
doi:

Substances chimiques

Mineralocorticoid Receptor Antagonists 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-509

Auteurs

Nicolas Melis (N)

a Laboratory of Cellular and Molecular Biology , Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.

Raphael Thuillier (R)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.
d CHU Poitiers , Service de Biochimie , Poitiers , France.
e Fédération Hospitalo-Universitaire SUPORT , Poitiers , France.

Clara Steichen (C)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.

Sebastien Giraud (S)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.
d CHU Poitiers , Service de Biochimie , Poitiers , France.

Yse Sauvageon (Y)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.

Jacques Kaminski (J)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.

Thomas Pelé (T)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.

Lionel Badet (L)

f Faculté de Médecine , Université Claude Bernard Lyon 1 , Villeurbanne , France.
g Hospices Civiles de Lyon , Service d'urologie et de chirurgie de la transplantation , Lyon , France.

Jean Pierre Richer (JP)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.
h CHU de Poitiers , Service de chirurgie générale et endocrinienne , Poitiers , France.
i Faculté de Médecine et de Pharmacie , ABS Lab (Laboratoire d'Anatomie, Biomécanique et Simulation), Université de Poitiers , Poitiers , France.

Jonatan Barrera-Chimal (J)

j Laboratorio de Fisiología Cardiovascular y Trasplante Renal, Unidad de Medicina Traslacional , Instituto de Investigaciones Biomédicas, UNAM and Instituto Nacional de Cardiología Ignacio Chávez , Mexico City , Mexico.

Frédéric Jaisser (F)

k INSERM, UMRS 1138, Team 1 , Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris, Descartes University , Paris , France.

Michel Tauc (M)

l LP2M CNRS-UMR7370, LabEx ICST , Medical Faculty, Université Côte d'Azur , Nice , France.

Thierry Hauet (T)

b IRTOMIT , Inserm U1082 , Poitiers , France.
c Faculté de Médecine et de Pharmacie , Université de Poitiers , Poitiers , France.
d CHU Poitiers , Service de Biochimie , Poitiers , France.
e Fédération Hospitalo-Universitaire SUPORT , Poitiers , France.
i Faculté de Médecine et de Pharmacie , ABS Lab (Laboratoire d'Anatomie, Biomécanique et Simulation), Université de Poitiers , Poitiers , France.
m IBiSA Plateforme 'plate-forme MOdélisation Préclinique - Innovation Chirurgicale et Technologique (MOPICT)', Domaine Expérimental du Magneraud , Surgères , France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH